Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
- Written by PR Newswire
![]() |
Summary of Study Outcomes
- ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints
- The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% positive predictive value (secondary endpoint) considerably...